These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 30419345)

  • 21. Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer.
    Sivaganesh V; Promi N; Maher S; Peethambaran B
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33670942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.
    Byrd TT; Fousek K; Pignata A; Szot C; Samaha H; Seaman S; Dobrolecki L; Salsman VS; Oo HZ; Bielamowicz K; Landi D; Rainusso N; Hicks J; Powell S; Baker ML; Wels WS; Koch J; Sorensen PH; Deneen B; Ellis MJ; Lewis MT; Hegde M; Fletcher BS; St Croix B; Ahmed N
    Cancer Res; 2018 Jan; 78(2):489-500. PubMed ID: 29183891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer.
    Cao W; Li J; Hao Q; Vadgama JV; Wu Y
    Breast Cancer Res; 2019 Feb; 21(1):29. PubMed ID: 30791936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent Progress in Triple Negative Breast Cancer Research.
    Mouh FZ; Mzibri ME; Slaoui M; Amrani M
    Asian Pac J Cancer Prev; 2016; 17(4):1595-608. PubMed ID: 27221827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An overview of triple negative breast cancer for surgical oncologists.
    Sharma S; Barry M; Gallagher DJ; Kell M; Sacchini V
    Surg Oncol; 2015 Sep; 24(3):276-83. PubMed ID: 26092709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer.
    Dees S; Ganesan R; Singh S; Grewal IS
    Mol Cancer Ther; 2020 Dec; 19(12):2409-2421. PubMed ID: 33087511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer.
    Tong L; Yu X; Wang S; Chen L; Wu Y
    Breast Cancer (Dove Med Press); 2023; 15():647-658. PubMed ID: 37644916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
    Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M
    Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification.
    Wang XZ; Liu Q; Sun JJ; Zuo WS; Hu DW; Ma SG; Mu DB; Yu ZY
    Genet Mol Res; 2015 Apr; 14(2):4282-90. PubMed ID: 25966200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Kwa MJ; Adams S
    Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.
    Khosravi-Shahi P; Cabezón-Gutiérrez L; Custodio-Cabello S
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):32-39. PubMed ID: 28815913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An overview of triple-negative breast cancer.
    Kumar P; Aggarwal R
    Arch Gynecol Obstet; 2016 Feb; 293(2):247-69. PubMed ID: 26341644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
    Williams CB; Soloff AC; Ethier SP; Yeh ES
    Adv Cancer Res; 2015; 127():253-81. PubMed ID: 26093903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
    Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The viral approach to breast cancer immunotherapy.
    Arab A; Behravan N; Razazn A; Barati N; Mosaffa F; Nicastro J; Slavcev R; Behravan J
    J Cell Physiol; 2019 Feb; 234(2):1257-1267. PubMed ID: 30146692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of CD22 in Triple-Negative Breast Cancer: A Novel Prognostic Biomarker and Potential Target for CAR Therapy.
    Zaib T; Cheng K; Liu T; Mei R; Liu Q; Zhou X; He L; Rashid H; Xie Q; Khan H; Xu Y; Sun P; Wu J
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Obesity Paradox in Cancer, Tumor Immunology, and Immunotherapy: Potential Therapeutic Implications in Triple Negative Breast Cancer.
    Naik A; Monjazeb AM; Decock J
    Front Immunol; 2019; 10():1940. PubMed ID: 31475003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
    Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
    World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Research progress on immunotherapy in triple‑negative breast cancer (Review).
    Zhang X; Ge X; Jiang T; Yang R; Li S
    Int J Oncol; 2022 Aug; 61(2):. PubMed ID: 35762339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.